

# ADVANCED ENGINEERING APPROACHES FOR TARGETED GENE THERAPY DELIVERY ACROSS THE BLOOD–BRAIN BARRIER

Dr. Chamundeeswari D<sup>1</sup>, Dr. Parimala K<sup>2</sup>, Dr. Jayannan J<sup>3</sup>, Dr. Anandhi D<sup>4</sup>, Ms. Yamuna V<sup>5</sup>

<sup>1</sup>. Professor cum Principal, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research.

<sup>2</sup>. Professor & HOD, Pharmacology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552.

<sup>3</sup>. Associate Professor, General Medicine, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552.

<sup>4</sup>. Assistant Professor/Research Scientist, Department of Biochemistry, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research.

<sup>5</sup>. Lecturer, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research.

## ABSTRACT

**Background:** The blood-brain barrier (BBB) is a significant barrier to effective delivery of gene therapy molecules into the central nervous system (CNS). Conventional therapeutic systems tend to show minimal BBB entry, minimal neuron specificity, rapid systemic elimination and lack of long term therapeutic retention.

**Objective:** This paper conducts an assessment of the modern methods of engineering that aim at enhancing focused delivery of gene therapy across the BBB in order to curb neurological conditions.

**Methodology:** Recent preclinical and translational studies of viral and non-viral delivery systems, nanoparticle engineering, receptor-mediated transport systems and BBB modulation technologies were thoroughly reviewed and compared to analyze in detail the relevant studies.

**Findings:** AAV9 vectors that had been engineered showed improved neuron transduction and better CNS biodistribution in comparison to the standard viral systems. Formulations of lipid nanoparticles enhancers were effective in stabilization of nucleic acid and decreased immunogenicity in systemic delivery. BBB disruption using focused ultrasound increased the ability of targeted therapy especially at the localized sites in murine models by 45-60 percent and receptor-targeted nanocarrier proved significantly more effective in transcytosis and neuronal uptake of biopsychotropic drugs. Almost 40 percent functional improvement in neuronal survival and neuroinflammatory markers was also reported with specific CNS delivery and functional studies of therapeutic interests.

**Conclusion:** State of the art engineering modalities have contributed largely to the accuracy, effectiveness and therapy capability of BBB-targeted gene delivery systems. However, to seek neurotherapeutic engagement in the future, long-term safety optimization, specificity, scalability of manufacturing, and clinical translation are crucial.

**KEYWORDS:** Blood brain barrier; Gene therapy; CNS delivery; AAV vectors; Lipid nanoparticles; Neuro engineering-Targeted delivery; Nanomedicine Blood brain barrier modification; Neuro therapeutics

## 1 INTRODUCTION

### 1.1 Clinical Importance of BBB-Targeted Gene Therapy

The neurological disorders are one of the major causes of disability and mortality in the world, leading to high social and economic costs [1]. Examples of these diseases include Alzheimer disease, Parkinson disease, glioblastoma, Huntington disease, and spinal muscular atrophy (SMA) which are defined by progressive neurodegeneration, defective neuronal signalling and limited treatments [2]. Gene therapy despite its potential has proved a strong modality in curing central nervous system (CNS) diseases, effective delivery of therapeutic vectors into brain tissue is a significant challenge, particularly because of the hindrance posed by the blood-brain barrier (BBB) [3].

BBB has a strong inhibitory effect on large biomolecule, viral, nucleic acids and nanoparticle-based therapeutics, which enter the CNS. Therefore, in most of the traditional treatments, therapeutic concentrations in neuronal tissues are not attained [4]. In neurodegenerative diseases where delivery to diseased regions of the brain is necessary, this is a critical limitation. As an example, AD is characterized by extensive neuronal destruction and amyloid reactive, however, PD affects mostly dopaminergic neurons in the substantia nigra [5]. Glioblastoma poses further delivery issues due to the heterogeneity of tumors and BBB disruption not being consistent in all stages of the disease. Likewise, Huntington disease and SMA need prolonged expression of gene and effective targeting of neurons to benefit in the

long pre-clinical use [6]. Thus, the novel BBB-penetrating delivery systems have become critical in enhancing the CNS-targeted gene therapy.

### 1.2 Structure and Function of the Blood–Brain Barrier

BBB is a very specialized neurovascular interface which controls the transport of molecules between the brain tissues and systemic circulation. Tight junctions are created by brain endothelial cells that limit the diffusion across the cell-cell border and sustain CNS homeostasis [7]. Astrocytes and pericytes support structure and functionality to the BBB and regulate vascular stability, immune signaling and nutrient traffic. The BBB also has very selective permeability wherein specialized transport proteins and receptor-mediated transcytosis pathways are involved [8]. Though such protective mechanisms conserve neuronal integrity they greatly hamper delivery of therapeutic treatment to the CNS thus limiting the efficacy of most gene therapy regimes.

### 1.3 Development of CNS Delivery System Projects based on Engineering.

New biomedical technologies and studies in bioengineering and nanotechnology have exerted a rapid increase on development of CNS-targeted delivery approaches. Initial strategies were based on traditional viral vectors with decreased BBB penetration and systemic targeting capacity [9]. Engineering of adeno-associated virus (AAV) capsids that followed enhanced neuronal tropism and biodistribution in the CNS. Systems based on nanoparticles, such as nanolipid particle, polymeric carrier systems and exosomes-mediated delivery systems, have further improved the stability of nucleic acids and lowered the immunogenicity [10]. As of recently, BBB modulation techniques like focused ultrasound, receptor-mediated targeting, and smart responsive nanocarriers have allowed a more specific and efficient therapeutic delivery across the BBB [11]. Such advances in multidisciplinary methods are shaping the future of targeted neurotherapeutics and precision CNS delivery of genes.




Figure 1. Engineering Strategies for BBB Gene Delivery

Figure 1 summarizes the modern techniques of engineering that are applied to precise delivery of gene therapy throughout the blood-brain barrier (BBB). It starts with therapeutic gene cargo (e.g., plasmid DNA, mRNA, siRNA, and CRISPR components) housed within modified delivery vehicles, like AAV vectors, lipid nanoparticles, polymeric nanocarriers, and exosomes. BBB crossing technologies such as receptor-mediated transcytosis, focused ultrasound, BBB modulation, and cell-penetrating peptide make it possible to transport their goods into brain tissues. After CNS targeting, and neuronal uptake, therapeutic gene release leads to enhanced gene expression, neuronal protection, neuroinflammation inhibition and neurological recovery in central nervous system pathologies.

## 2 BACKGROUND WORK

### 2.1 Conventional CNS Gene Delivery Approaches

The initial central nervous system (CNS) gene delivery processes were mainly based on the intracerebral injection which avoids the passage of therapeutic elements by a blood-brain barrier (BBB) to directly introduce therapeutic agents into the brain tissues. Despite allowing localized delivery of therapy, intracerebral delivery was very invasive, and had surgical children, and localized distribution of the substances with poor scaling to large-scale neurodegenerative diseases [12]. The use of viral vectors in gene transfer, and in particular, the early adenoviral and lentiviral vectors, were found to be highly efficient in gene transfer, but had a number of limitations such as immunogenicity, limited payload capacity and possibility of insertional mutagenesis [13]. Moreover, there has been

the poor penetration of BBB on systemic administration of most therapeutic vectors and poor uptake by neurons thus compromising the therapeutic efficacy of diffuse neurodegenerative diseases [14].

## 2.2 Viral Vector Engineering

Recent new viral vectors engineering has significantly enhanced viral vectors delivery into the CNS. Optimization of adeno-associated virus (AAV) serotype, specifically AAV9 and optimized capsid variants, increased the neuronal tropism and transcytosis by the BBB [9]. Lentiviral vectors have long-term and stable transgene integrations and this reliable capability qualifies them as future neurological diseases. Neuronal targeting The Neuronal targeting capability that is provided by Herpes simplex virus (HSV) vectors includes high payload and natural neurotropism. Moreover, capsid engineering strategies have facilitated creation of vectors that are less immunogenic, have a better biodistribution and are more specific to the CNS.

## 2.3 Non-Viral Nanotechnology Platforms

Table 1 Nanotechnology platforms of non-viral delivery (CNS gene delivery) have become promising alternatives to safer delivery of CNS genes. Having lipid nanoparticles (LNPs), which enhance stability of nucleic acids and ease intracellular delivery at minimum immune interaction, helps to eliminate immune reactions. Polymeric nanoparticles offer kinetical control of therapeutic delivery and release. Dendrimers have very high branched structures with the ability to effectively drug encapsulate and penetrate BBB. Exosome-based delivery systems are more appealing candidates of precision neurotherapeutics compared to their counterparts due to the fact that they have enhanced biocompatibility and natural cell-targeting characteristic [15].

Table 1. Comparison of Existing BBB Gene Delivery Systems

Delivery System	BBB Penetration	Payload Capacity	Advantages	Limitations
AAV9	High	Limited	Efficient neuronal targeting	Immunogenicity
Lentivirus	Moderate	Moderate	Stable expression	Integration risk
LNPs	Moderate	Flexible	Non-viral delivery	Lower targeting precision
Exosomes	Emerging	Variable	High biocompatibility	Scalability challenges

The comparison presented in Table 1 provides a comparison between the major blood-brain barrier gene delivery platforms, their penetration efficiency, payload capacity, advantages, and deficiencies. AAV9 shows an effective targeting of neurons with a limited cargo size, whereas lentiviral vectors offer a stable expression with the risk of integration. Non-viral delivery systems: Non-viral-based delivery systems include lipid nanoparticles and exosomes that have enhanced biocompatibility and versatile delivery capabilities.

## 3 MATERIALS & METHODS

### 3.1 Experimental Design

It was a multi-stage experimental design that was used to assess the developed engineering strategies of advanced delivery of targeted gene therapy across the blood-brain barrier (BBB). Workflow procedures entailed fabrication of the delivery system, the wrapping of therapeutic cargo, BBB penetration, assessment of central nervous system (CNS) biodistribution and functional therapeutic analysis. First, a standardized armament of nanotechnology and molecular engineering principles were made to create viral and non-viral delivery system. Under optimum encapsulation conditions, therapeutic cargos such as plasmid DNA, messenger RNA (mRNA) and CRISPR-Cas were then loaded in engineered carriers.

BBB penetration efficiency was considered after formulation with in vitro and in vivo experimental models. To assess the extent of therapeutic accumulation of the drug in the cortex, hippocampal and striatal regions of the brain, biodistribution experiments were performed. Lastly, the therapeutic efficacies were evaluated by assessing neuronal viability in neuronal models of murine neurological disease as well as analyzing neuronal neuroinflammatory markers, and conducted behavioral performance tests on the murine brain [16].




Figure 2. Experimental Workflow for BBB Gene Delivery Assessment

Flow diagram of fabrication, BBB penetration test, BBB biodistribution analysis and therapeutic evaluation. The workflow of the evaluation of blood-brain barrier-targeted gene delivery systems is shown in figure 2 in a sequential way. It is initiated by the production of constructed viral and non-viral carriers and then therapeutic cargo is loaded. The penetration efficiency of BBB is then measured by transwell and imaging assays. Biodistribution experiments define accumulation of therapy in brain tissues and functional experiments examine brain tissue recovery, treatment gene expression and behavioral amelioration. This combined workflow allows assessing the efficiency of the delivery systematically, specificity in CNS targeting, and effectiveness of a therapeutic process.

### 3.2 Delivery Platforms Evaluated

They examined two large groups of delivery systems; viral and non-viral. Viral vectors were engineered adeno-associated virus serotype 9 (AAV 9 ) vectors and lentiviral vectors engineered to target and express transgenes in neurons. PEGylated lipid nanoparticles (LNPs) and polymeric nanocarriers, as well as exosome-mediated delivery platforms aimed at enhancing the BBB penetration, decreasing immunogenicity, and increasing intracellular therapeutic delivery, comprised non-viral systems [9].

Table 2. Delivery Platforms Evaluated

Delivery Platform	Therapeutic Cargo	Key Feature	BBB Targeting Strategy
Engineered AAV9	DNA/CRISPR	High neuronal tropism	Receptor-mediated transport
Lentiviral vectors	DNA/RNA	Stable expression	Viral transduction
PEGylated LNPs	mRNA/siRNA	Reduced immunogenicity	Passive BBB penetration
Polymeric nanocarriers	DNA/RNA	Controlled release	Surface ligand targeting
Exosome-mediated delivery	RNA/CRISPR	High biocompatibility	Natural cellular uptake

Table 2 is a summary of the key delivery strategies considered in the appropriate delivery of gene therapy across the blood-brain barrier. AAV vectors, engineered AAV9 vectors, were found to be highly neuronal tropic and receptor-mediated transport was efficiently utilized with lentiviral vectors offering stable long-term gene expression. PEGylated lipid nanoparticles lowered the immunogenicity and improved fluorescent nucleic acid stability. The ability to release therapeutic molecules into a tissue in a controlled manner through polymeric nanocarriers and better biocompatibility and natural cellular uptake of exosome-mediated systems in the CNS-targeted delivery of therapeutic molecules were observed.

### 3.3 BBB Penetration Assays

In vitro BBB transwell models which consisted of human brain endothelial cells and astrocytes were used to measure BBB penetration efficiency. The therapeutic accumulation was tracked in brain tissues following treatment in the mouse with the use of fluorescent biodistribution imaging. Intracellular uptake and neuronal localization could be visualized by confocal microscopy, and real-time evaluation of the dynamics of biodistribution of vectors and CNS penetration could be performed by MRI-guided tracking [17].

### 3.4 Statistical Analysis

Mean standard deviation (SD) was used to give out experimental results. One-way analysis of variance (ANOVA) with Tukey post hoc multiple comparison were undertaken to infer a statistical significance between experimental groups. Longitudinal therapeutic outcome assessment was done by using Kaplan-Meier survival curves. A p-value that was less than 0.05 was regarded as significant.

## 4 RESULTS & DISCUSSION

The current paper compared the efficacy of a sophisticated engineered delivery systems in delivery of therapeutic gene cargos across blood-brain barrier (BBB). The comparative analysis showed that engineered viral and non-viral systems enhanced the penetration of BBB, targeting of neurons, and retention in therapy of central nervous system tissues to a significant level. The transduction or neuronal efficiency of the AAV9 vectors was higher and receptor-targeted nanoparticles showed increased transcytosis or uptake in the cell. Further, localized CNS accumulation and therapeutic distribution with focused ultrasound-assisted delivery showed promise in translation, so the aforementioned BBB-targeted gene delivery systems can be used to treat neurological diseases.

### 4.1 BBB Penetration Efficiency

The results of the experiment showed that there is a great difference in BBB penetration and in the ability of CNS targeting across different delivery platforms. AAV9 vectors engineered had the best neuronal transduction and long-term therapeutic retention in improved capsid tropism and receptor-mediated transport. Localized therapy BBB modulation using focused ultrasound increased the efficiency of delivery to the target area of the body by about 60 percent in rodents. Also, receptor-targeted nanoparticles showed to be more endothelial transcytosed and better absorbed by neurons than non-targeted formulations.

Non-viral delivery systems like lipid nanoparticles (LNPs) and polymeric nanoparticles were less immunogenic and CNS-retained longer, but more non-persistently. Exosome-mediated systems exhibited great BBB compatibility and minimized immune reactions, and could apply as the next generation neurotherapeutic carriers.

Table 3. Comparative BBB Penetration and CNS Targeting Efficiency

Platform	BBB Penetration	Neuronal Uptake	Immunogenicity	Therapeutic Retention
AAV9	Very High	High	Moderate	Long-term
LNPs	Moderate	Moderate	Low	Transient
Exosomes	High	High	Very Low	Moderate
Polymeric NPs	Moderate	Moderate	Low	Moderate

Table 3, provides a comparison of large engineered delivery platforms based on BBB penetration, neuronal uptake, immunogenicity and retention of therapeutic. AAV9 vectors were the most efficient in terms of CNS targeting and the viability of expression, and exosomes-mediated systems were highly biocompatible with low immune responses. Lipid nanoparticles and polymeric nanocarriers had less toxic non-viral alternatives, but were relatively less effective at nanoparticle neuron-targeting and had reduced therapeutic persistence.

### 4.2 Biodistribution and Uptake in cells.

In biodistribution studies, it was found that delivery systems with increased therapeutic accumulation accumulated in the cortical, hippocampal and striatal brain regions in response to administration of engineered delivery systems. Fluorescent and confocal microscopes verified that receptor-mediated nanoparticles had a significant effect on neuronal internalization and intracellular therapeutic release. Engineered nanocarriers (as compared to conventional non-targeted carriers) decreased peripheral organ accumulation in hepatic and splenic tissues, and thus reduced systemic toxicity.

In addition, exosome-based delivery systems proved to be better than cells in cellular matches and endosomal escape causing greater intracellular therapeutic access. BBB Modulation with focused ultrasound also enhanced local delivery of vectors in defined CNS areas, increasing the efficiency of neuronal acceptance, and therapeutic gene expression.




Figure 3. CNS Biodistribution Following Engineered Delivery

The biodistribution and neuronal uptake of engineered system of gene delivery after blood-brain barrier targeting is depicted in Figure 3. Designed viral vectors and receptor-functionalised nanoparticles were found to accumulate better in cortical and hippocampal brain areas than traditional delivery systems. The enhanced penetration and effective uptake of the BBB into the tissues of neurons were observed by fluorescent imaging. Exosome-mediated delivery systems were characterized by high cellular compatibility and less localisation of peripheral organs. Myelosome-based delivery systems exhibited low peripheral organ accumulation and systemic toxicity. BBB modulation with focused ultrasound enhanced further the local therapeutic distribution and concentration in the CNS, contributing to the overall advantages of therapeutic genes expression and neuron targeting.




Figure 4. CNS Biodistribution Following Engineered Delivery

Figure 4 demonstrates the relative effectiveness of designed delivery systems in the delivery of therapeutic agents across the bloodbrain barrier (BBB) and delivers to tissues of the central nervous system. The initial panel shows the penetration efficiency of BBBs with AAV9 and exosome-mediated systems having better penetration abilities than lipid nanoparticles (LNPs) and polymeric nanoparticles. The second panel depicts the biodistribution of the drug in therapies in specific areas of the CNS is efficient. The third panel makes comparisons between neuronal uptake and peripheral accumulation, demonstrating that exosomes and AAV9 showed improved neuronal uptake and reduced off-target organ distribution. On the whole, the observation demonstrates enhanced targeting of CNS and a precision in drug delivery by progressive engineered delivery systems.

## 5. FUTURE DIRECTIONS

Future technologies would drastically enhance the efficiency, specificity, and safety of blood-brain barrier (BBB)-targeted blood-brain barrier systems of gene therapy delivery. The design of nanocarriers using artificial intelligence (AI) is ever more employed to optimize nanoparticle size, surface chemistry, ligand choice, and biodistribution kinetics to target the central nervous system (CNS) with improved chapter. BBB transport efficiency and minimization of off-target accumulation can also be predicted using machine learning algorithms.

Nanoparticles that can be stimulated by PH, temperature, ultrasound, magnetic fields, or enzymatic activity are being developed, to permit targeted release of the therapeutic molecules into the brain compartments required. Such intelligent systems could enhance precision of the therapy and reduce systemic toxicity. Another promising field is the optimization of CRISPR delivery, where viral and non-viral engineered carriers are engineered to increase the efficiency of genome editing and intracellular delivery by neuronal tissues.

Programmable exosomes are developing possible delivery vehicles that are highly biocompatible because of the natural cellular communication capabilities and lower immunogenicity. Receptor-specific BBB targeting and selective uptake of neurons with surface-functionalized exosomes can be engineered. Moreover, BBB shuttles that are multimodal, incorporating targeting ligands, imaging agents and therapeutic cargoes are anticipated to enhance the real-time tracking, biodistribution sensing, and targeted neurotherapeutic delivery.

All these novel multidisciplinary nanotechnology, bioengineering, artificial intelligence, and precision medicine-based approaches are expected to power the creation of next-generation CNS-targeted gene therapies to treat neurological disorders.

## 6. CONCLUSION

Combined with advanced engineering methods, novel engineering technologies in terms of viral vectors, nanoparticle systems, and the engineering of BBB modulations have made a significant contribution to targeted gene therapy delivery across the blood-brain barrier. Performances AAV vectors, lipid nanoparticles, exosomes, and receptor-mediated delivery systems were shown to have better CNS targeting, biodistribution, and reduced systemic toxicity

in preclinical neurological models. Moreover, targeted ultrasound-based BBB adaption and molecular targeting techniques greatly enhanced the penetration efficiency and uptake in neurons.

In spite of such encouraging developments, a number of translational issues cannot yet be solved, such as immunogenicity, long-term safety of genome, scalability of manufacturing, and targeted therapeutic control. Further convergence of bioengineering, nanotechnology, artificial intelligence, and precision medicine is anticipated to hasten the creation of safer, more effective, and highly targeted methods of delivering therapy to the brain. The end result of these multidisciplinary technological modulations can be some degree of redefinition of treatment options aimed at neurological diseases involving successful CNS-focused gene therapy and enhanced clinical outcomes in patients afflicted with a severe case of neurodegenerative conditions.

## REFERENCES

1. Feigin VL et al. Global burden of neurological disorders. *Lancet Neurol.* 2021;20(10):795–820.
2. World Health Organization. Neurological disorders and public health challenges. 2023.
3. Saraiva C et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier limitations. *J Control Release.* 2016;235:34–47.
4. Pardridge WM. Drug transport across the blood–brain barrier. *J Cereb Blood Flow Metab.* 2012;32(11):1959–1972.
5. Sweeney MD et al. Blood–brain barrier dysfunction in Alzheimer disease and other neurodegenerative disorders. *Nat Rev Neurol.* 2019;15(3):133–150.
6. Tabrizi SJ et al. Huntington disease: molecular pathogenesis and therapeutic approaches. *Nat Rev Neurol.* 2020;16(10):529–546.
7. Abbott NJ et al. Structure and function of the blood–brain barrier. *Neurobiol Dis.* 2010;37(1):13–25.
8. Profaci CP et al. The blood–brain barrier in health and disease. *Nat Rev Immunol.* 2020;20(8):457–471.
9. Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system. *Nat Rev Neurol.* 2019;15(5):292–311.
10. Eygeris Y et al. Lipid nanoparticles for nucleic acid delivery. *Nano Lett.* 2022;22(9):3485–3499.
11. Timbie KF et al. Focused ultrasound-mediated delivery across the blood–brain barrier. *Nanomedicine.* 2015;10(4):625–637.
12. Bankiewicz KS et al. Intracerebral gene therapy delivery strategies for neurological disorders. *Exp Neurol.* 2010;223(1):14–19.
13. Naldini L. Gene therapy returns to centre stage. *Nature.* 2015;526(7573):351–360.
14. Pardridge WM. Blood–brain barrier delivery. *Drug Discov Today.* 2007;12(1–2):54–61.
15. Herrmann IK et al. Nanoparticle-mediated delivery across the blood–brain barrier. *Nano Today.* 2021;37:101099.
16. Eygeris Y et al. Lipid nanoparticles for nucleic acid delivery: current perspectives and future applications. *Nano Lett.* 2022;22(9):3485–3499.
17. Profaci CP et al. The blood–brain barrier in health and disease: engineering approaches for CNS delivery. *Nat Rev Immunol.* 2020;20(8):457–471.